Provided by Tiger Trade Technology Pte. Ltd.

Larimar Therapeutics, Inc.

4.05
-0.1300-3.11%
Post-market: 3.93-0.1200-2.96%19:30 EDT
Volume:945.55K
Turnover:3.84M
Market Cap:421.20M
PE:-2.10
High:4.23
Open:4.23
Low:3.93
Close:4.18
52wk High:6.42
52wk Low:2.72
Shares:104.00M
Float Shares:57.54M
Volume Ratio:0.98
T/O Rate:1.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9258
EPS(LYR):-2.2711
ROE:-139.63%
ROA:-70.96%
PB:3.31
PE(LYR):-1.78

Loading ...

Larimar Therapeutics Q2 EPS USD -0.3

THOMSON REUTERS
·
Aug 04

Larimar Therapeutics - Projects Cash Runway into Q3 2027

THOMSON REUTERS
·
Aug 04

Larimar Therapeutics Q2 Net Income USD -32.782 Million

THOMSON REUTERS
·
Aug 04

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

THOMSON REUTERS
·
Aug 04

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
Jul 14

Larimar Therapeutics director buys $167K in common stock

TIPRANKS
·
Jul 09

Larimar Therapeutics Director Thomas Edward Hamilton Acquires USD 166,890 of Common Shares

Reuters
·
Jul 09

Adobe, Larimar, Palantir, Chevron, eXp Trending With Analysts

TIPRANKS
·
Jul 04

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 30

Larimar Therapeutics selloff a buying opportunity, says Citi

TIPRANKS
·
Jun 30

Nomlabofusp Progress and Durable Efficacy Support Buy Rating on LRMR with Unchanged $25 Price Target

TIPRANKS
·
Jun 30

Larimar stumbles on safety news even as BLA submission kicks off

TIPRANKS
·
Jun 29

Larimar Tumbles as Safety Concerns Resurface in Rare Disease Drug Study Update

Reuters
·
Jun 29

Top Premarket Decliners

MT Newswires Live
·
Jun 29

Larimar Therapeutics submits first module of rolling BLA for nomlabofusp

TIPRANKS
·
Jun 29

Larimar Therapeutics Submits First Module of Rolling BLA to FDA for Nomlabofusp in Friedreich’s Ataxia

Reuters
·
Jun 29

Larimar Therapeutics - First Patient Dosing in Phase 3 Study Expected Q3 2026

THOMSON REUTERS
·
Jun 29

Larimar Therapeutics - Nomlabofusp Long-term Dosing Generally Well-tolerated; Anaphylaxis in 10 of 43 Patients

THOMSON REUTERS
·
Jun 29

Larimar Therapeutics - Submits First Module of Rolling Bla for Nomlabofusp; Remaining Modules Expected 2H 2026

THOMSON REUTERS
·
Jun 29

Larimar Therapeutics to Host Investor Webcast on Nomlabofusp Program for Friedreich’s Ataxia

Reuters
·
Jun 27